Education

Biography

Dr. Yang obtained her PhD from the Cancer Research Institute, Xiangya Medical School, Central South University at 2002, where she developed a strong interest in the cancer research of nasopharyngeal carcinoma. In 2004, she came to the United States to begin her postdoctoral training at the Myeloma Institute for Research and Therapy, University of Arkansas, and then joined the Fellowship Program of the Department of Lymphoma and myeloma at The University of Texas M. D. Anderson Cancer Center in Dr. Qing Yi’s laboratory. She was recruited as an instructor at 2008. In her period of training, she published first-author research articles in high impact journals such as Cancer Cell (2006, 2007) and Blood (2007), and received awards/fellowships from the NIH/NCI K99/R00 Award, the American Society of Hematology, the International Myeloma Foundation, the AACR Scholar-in-Training Award, and the MD Anderson Altana-Pharma Award for Outstanding Publications. Dr. Yang has been a tenure-track assistant professor in the Division of Cancer Medicine at the MD Anderson Cancer Center in Houston, TX, since 2011. Her laboratory is working in the field of translational research in multiple myeloma, focusing on tumor microenvironment. High-impact research papers related to myeloma-associated chemotherapy resistance and osteolytic bone lesion have been published in Leukemia, Cancer Research, and other journals. Her studies are now supported by the NIH/NCI via an R01 Grant, MD Anderson MM SPORE Program, the American Society of Hematology, the Leukemia Research Foundation, and other notable foundations.

Research Interest

Her laboratory oversees the translational research of multiple myeloma, with a specific focus on tumor microenvironment. Multiple myeloma is a hematological malignancy, and this disease remains fatal. The majority of myeloma patients go into a relapsed or refractory stage of the disease after treatment. One of our goals is to investigate the role of bone marrow micro environment as a tumor bed in myeloma drug resistance. In addition, bone destruction is a hallmark of multiple myeloma. Patients with osteolysis have severe bone pain and a high risk of fractures, which can drastically affect their overall quality of life. Myeloma cells increase osteo clast-mediated bone resorption and decrease osteo blast-mediated bone formation and the resorbed bone thereby releases growth factors into marrow to support myeloma growth and survival. We focus our studies on how myeloma cells regulate bone cells and break bone remodeling. Our current studies include (1) the role of bone marrow adipocytes and adipocyte-derived adipokines in protection of myeloma cells against chemotherapy-induced apoptosis,(2) the role of myeloma-expressed p38 MAPK, and (3) a micro evironmental factor, C-reactive protein, in myeloma-associated osteolytic bone lesion. Additionally, we use molecular biological technology, preclinical animal studies, and human translational studies to find out new target candidates and approaches, and apply of these findings into the effective treatments for myeloma patients.

Professional Activities:

Honors And Awards

Scholarship of Central South University in China, Central South University in China, 2001
Tan Jiazhen-Fudan University Life Science Award in China, Tan Jiazhen-Fudan University, 2001
National Nature Science Foundation of China, National Nature Science Foundation of China, 2003-2004
Altana Pharma Publication Award, MD Anderson Cancer Center, 2006
ASH Travel Award, 49th American Society of Hematology, 2007
ASH Scholar Award, American Society of Hematology, 2008-2010
Brian D. Novis Research Award, International Myeloma Foundation, 2008
Fellowship, Lymphoma Research Foundation, 2008
K99/R00, National Cancer Institute, 2009-present
ASH Scholar Junior Faculty Award, American Society of Hematology, 2012-present

Publications

Peer-Reviewed Original Research Articles

1. Xie J, Qian J, Yang J, Wang S, Freeman ME 3rd and Yi Q, et al. Critical roles of Raf/MEK/ERK and PI3K/AKT signaling and inactivation of p38 MAP Kinase in the differentiation and survival of monocyte-derived immature dendritic cells. Exp Hematol 33(5):564-72, 5/2005. PMID: 15850834.
2. Ding L, Li L, Yang J, Tao Y, Ye M, Shi Y, Tang M, Yi W, Li X, Gong J, Cao Y. Epstein-Barr virus encoded latent membrane protein 1 modulates nuclear translocation of telomerase reverse transcriptase protein by activating nuclear factor-kappaB p65 in human nasopharyngeal carcinoma cells. Int J Biochem Cell Biol 37(9):1881-1889, 8/2005. PMID: 15967702.
3. Song X, Tao Y, Zeng L, Yang J, Tang F, Lee LM, Gong J, Wu Q, Cao Y. Epstein-Barr virus-encoded latent membrane protein 1 modulates cyclin D1 by c-Jun/Jun B heterodimers. Sci China C Life Sci 48(4):385-393, 8/2005. PMID: 16248432.
4. Qian J, Wang S, Yang J, Xie J, Lin P, Freeman ME 3rd and Yi Q. Targeting heat shock proteins for immunotherapy in multiple myeloma: generation of myeloma-specific cytotoxic T lymphocytes using dendritic cells pulsed with tumor-derived gp96. Clin Cancer Res 11(24):8808-8815, 12/2005. PMID: 16361569.
5. Wang S, Yang J, Qian J, Wezeman M, Kwak LW, Yi Q. Tumor evasion of the immune system: inhibiting p38 MAPK signaling restores the function of dendritic cells in multiple myeloma. Blood 107(6):2432-9, 3/2006. e-Pub 11/2005. PMCID: PMC1895733.
6. Yang J, Qian J, Wezeman M, Wang S, Lin P, Wang M, Yaccoby S, Kwak LW, Barlogie B, Yi Q. Targeting beta2-microglobulin for induction of tumor apoptosis in human hematological malignancies. Cancer Cell 10(4):295-307, 10/2006. PMID: 17045207.
7. Wang S, Hong S, Yang J, Qian J, Zhang X, Shpall E, Kwak LW, Yi Q. Optimizing immunotherapy in multiple myeloma: Restoring the function of patients' monocyte-derived dendritic cells by inhibiting p38 or activating MEK/ERK MAPK and neutralizing interleukin-6 in progenitor cells. Blood 108(13):4071-7, 12/2006. e-Pub 8/2006. PMCID: PMC1895445.
8. Wang M, Zhang L, Han X, Yang J, Qian J, Hong S, Samaniego F, Romaguera J, Yi Q. Atiprimod inhibits the growth of mantle cell lymphoma in vitro and in vivo and induces apoptosis via activating the mitochondrial pathways. Blood 109(12):5455-62, 6/2007. e-Pub 2/2007. PMID: 17317853.
9. Ding L, Li L, Yang J, Zhou S, Li W, Tang M, Shi Y, Yi W, Cao Y. Latent membrane protein 1 encoded by Epstein-Barr virus induces telomerase activity via p16(INK4A)/Rb/E2F1 and JNK signaling pathways. J Med Virol, 8/2007.
10. Qian J, Xie J, Hong S, Yang J, Zhang L, Han X, Wang M, Zhan F, Shaughnessy JD, Epstein J, Kwak LW, Yi Q. Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma. Blood 110(5):1587-94, 9/2007. e-Pub 5/2007. PMCID: PMC1975842.
11. Yang J, Wezeman M, Zhang X, Lin P, Wang M, Qian J, Wan B, Kwak LW, Yu L, Yi Q. Human C-reactive protein binds activating Fcgamma receptors and protects myeloma tumor cells from apoptosis. Cancer Cell 12(3):252-65, 9/2007. PMID: 17785206.
12. Yang J, Zhang X, Wang J, Qian J, Zhang L, Wang M, Kwak LW, Yi Q. Anti beta2-microglobulin monoclonal antibodies induce apoptosis in myeloma cells by recruiting MHC class I to and excluding growth and survival cytokine receptors from lipid rafts. Blood 110(8):3028-35, 10/2007. e-Pub 7/2007. PMCID: PMC2018676.
13. Wang S, Hong S, Wezeman M, Qian J, Yang J, Yi Q. Dendritic cell vaccine but not idiotype-KLH protein vaccine primes therapeutic tumor-specific immunity against multiple myeloma. Front Biosci 12:3566-75, 2007. e-Pub 5/2007. PMID: 17485322.
14. Wang M, Han XH, Zhang L, Yang J, Qian JF, Kwak LW, Romaguera J and Yi Q. Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leukemia 22(1):179-85, 1/2008. e-Pub 9/2007. PMID: 17898787.
15. Wang M, Zhang L, Han XH, Yang J, Qian J, Hong S, Lin P, Shi Y, Romaguera J, Kwak LW and Yi Q. A severe combined immunodeficient-hu in vivo mouse model of human primary mantle cell lymphoma. Clin Cancer Res 14(7):2154-60, 4/2008. PMID: 18381957.
16. Hong S, Qian J, Yang J, Li H, Kwak LW, Yi Q. Roles of idiotype-specific t cells in myeloma cell growth and survival: Th1 and CTL cells are tumoricidal while Th2 cells promote tumor growth. Cancer Res 68(20):8456-64, 10/2008. PMCID: PMC2575640.
17. Yang J, Cao Y, Hong S, Li H, QianJ, Kwak LW, and Yi Q. Human-like mouse models for testing the efficacy and safety of anti-beta2-microglobulin monoclonal antibodies to treat myeloma. Clin Cancer Res 15(3):951-9, 2/2009. PMCID: PMC2659684.
18. Qian J, Hong S, Wang S, Zhang L, Sun L, Wang M, Yang J, Kwak LW, Hou J, Yi Q. Myeloma cell line-derived, pooled heat shock proteins as a universal vaccine for immunotherapy of multiple myeloma. Blood 114(18):3880-9, 8/2009. e-Pub 8/2009. PMID: 19654406.
19. Zheng Y, Cai Z, Wang S, Zhang X, Qian J, Hong S, Li H, Wang M, Yang J, Yi Q. Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis. Blood 114(17):3625-8, 10/2009. e-Pub 8/2009. PMCID: PMC2766678.
20. Yang J and Yi Q. Killing tumor cells through their surface beta(2)-microglobulin or major histocompatibility complex class I molecules. Cancer 116(7):1638-45, 4/2010. PMCID: PMC2847067.
21. Li H, Hong S, Qian J, Zheng Y, Yang J, Yi Q. Crosstalk between the Bone and Immune systems: Osteoclasts Function as Antigen-Presenting Cells and Activate CD4+ and CD8+ T cells. Blood 116(2):210-7, 7/2010. e-Pub 3/2010. PMCID: PMC2910608.
22. Cao Y, Lan Y, Qian J, Zheng Y, Hong S, Li H, Wang M, Kwak LW, Lin D, Yang J, Yi Q. Targeting cell surface β2 -microglobulin by pentameric IgM antibodies. Br J Haematol 154(1):111-21, 7/2011. e-Pub 5/2011. PMCID: PMC3111817.
23. Qian J, Zheng Y, Zheng C, Wang L, Qin H, Hong S, Li H, Lu Y, He J, Yang J, Neelapu S, Kwak LW, Hou J, Yi Q. Active vaccination with Dickkopf-1 induces protective and therapeutic antitumor immunity in murine multiple myeloma. Blood 119(1):161-9, 1/2012. e-Pub 11/2011. PMCID: PMC3251227.
24. Sun L, Zhang L, Qian J, Yang J, Yi Q, Dong W, Wang M. Combination of atiprimod and the proteasome inhibitor bortezomib induces apoptosis of mantle cell lymphoma in vitro and in vivo. Leuk Res 36(3):363-8, 3/2012. e-Pub 10/2011. PMID: 22000823.
25. Hong S, Qian J, Li H, Yang J, Lu Y, Zheng Y, Yi Q. CpG or IFN-α are more potent adjuvants than GM-CSF to promote anti-tumor immunity following idiotype vaccine in multiple myeloma. Cancer Immunol Immunother 61(4):561-71, 4/2012. e-Pub 10/2011. PMID: 22002243.
26. Zheng Y, Yang J, Qian J, Zhang L, Lu Y, Li H, Lin H, Lan Y, Liu Z, He J, Hong S, Thomas S, Shah J, Baladandayuthapani V, Kwak LW, Yi Q. Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone. J Mol Med (Berl) 90(6):695-706, 6/2012. e-Pub 12/2011. PMID: 22207485.
27. Yang J, He J, Wang J, Cao Y, Ling J, Qian J, Lu Y, Li H, Zheng Y, Lan Y, Hong S, Matthews J, Starbuck MW, Navone NM, Orlowski RZ, Lin P, Kwak LW, Yi Q. Constitutive activation of p38 MAPK in tumor cells contributes to osteolytic bone lesions in multiple myeloma. Leukemia 26(9):2114-23, 9/2012. e-Pub 3/2012. PMCID: PMC3381862.
28. Hong S, Li H, Qian J, Yang J, Lu Y, Yi Q. Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity. Clin Exp Immunol 170(2):167-77, 11/2012. PMCID: PMC3482363.
29. Zhang L, Yang J, Qian J, Li H, Romaguera JE, Kwak LW, Wang M, Yi Q. Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells. Blood 120(18):3783-92, 11/2012. e-Pub 9/2012. PMCID: PMC3488890.
30. Lu Y, Hong S, Li H, Park J, Hong B, Wang L, Zheng Y, Liu Z, Xu J, He J, Yang J, Qian J, Yi Q. The helper 9 cells promote antitumor immune responses in vivo. J Clin Invest 122(11):4160-71, 11/2012. e-Pub 10/2012. PMCID: PMC3484462.
31. He J, Liu Z, Zheng Y, Qian J, Li H, Lu Y, Xu J, Hong B, Zhang M, Lin P, Cai Z, Orlowski RZ, Kwak LW, Yi Q, Yang J. p38 MAPK in Myeloma Cells Regulates Osteoclast and Osteoblast Activity and Induces Bone Destruction. Cancer Res 72(24):6393-402, 12/2012. e-Pub 10/2012. PMCID: PMC3525770.
32. Wang L, Zhao Y, Qian J, Sun L, Lu Y, Li H, Li Y, Yang J, Cai Z, Yi Q. Toll-like receptor-4 signaling in mantle cell lymphoma : Effects on tumor growth and immune evasion. Cancer 119(4):782-91, 2/2013. e-Pub 8/2012. PMID: 22915070.
33. Zheng Y, Yang J, Qian J, Qiu P, Hanabuchi S, Lu Y, Wang Z, Liu Z, Li H, He J, Lin P, Weber D, Davis RE, Kwak L, Cai Z, Yi Q. PSGL-1/selectin and ICAM-1/CD18 interactions are involved in macrophage-induced drug resistance in myeloma. Leukemia 27(3):702-10, 3/2013. e-Pub 9/2012. PMCID: PMC3652581.
34. Wang L, Qian J, Lu Y, Li H, Bao H, He D, Liu Z, Zheng Y, He J, Li Y, Neelapu S, Yang J, Kwak LW, Yi Q, Cai Z. Immune evasion evasion of mantle cell lymphoma: expression of B7-H1 leads to inhibited T-cell response to and killing of tumor cells. Haematologica 98(9):1458-66, 9/2013. e-Pub 3/2013. PMCID: PMC3762104.
35. Zhang L, Pham LV, Newberry KJ, Ou Z, Liang R, Qian J, Sun L, Blonska M, You Y, Yang J, Lin X, Rollo A, Tamayo AT, Lee J, Ford RJ, Zhao X, Kwak LW, Yi Q,Wang M. In vitro and in vivo therapeutic efficacy of carfilzomib in mantle cell lymphoma: targeting the immunoproteasome. Mol Cancer Ther 12(11):2494-504, 11/2013. e-Pub 8/2013. PMID: 23990113.
36. Liu Z, Xu J, Li H, Zheng Y, He J, Liu H, Zhong Y, Lu Y, Hong B, Zhang M, Lin P, Du J, Hou J, Qian J, Kwak LW, Yi Q, Yang J. Bone marrow stromal cells derived MCP-1 reverses the inhibitory effects of multiple myeloma cells on osteoclastogenesis by upregulating the RANK expression. PLoS One 8(12):e82453, 12/2013. e-Pub 12/2013. PMCID: PMC3858321.
37. Bjorklund CC, Baladandayuthapani V, Lin HY, Jones RJ, Kuiatse I, Wang H, Yang J, Shah JJ, Thomas SK, Wang M, Weber DM, Orlowski RZ. Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications. Leukemia 28(2):373-83, 2/2014. e-Pub 6/2013. PMCID: PMC3874423.
38. Park J, Li H, Zhang M, Lu Y, Hong B, Zheng Y, He J, Yang J, Qian J, Yi Q. Murine Th9 cells promote the survival of myeloid dendritic cells in cancer immunotherapy. Cancer Immunol Immunother 63(8):835-45, 8/2014. e-Pub 5/2014. PMID: 24841535.
39. Liu Z, Xu J, He J, Zheng Y, Li H, Lu Y, Qian J, Lin P, Weber DM, Yang J, Yi Q. A critical role of autocrine sonic hedgehog signaling in human CD138+ myeloma cell survival and drug resistance. Blood 124(13):2061-71, 9/2014. e-Pub 7/2014. PMCID: PMC4186536.
40. Zhang M, Qian J, Lan Y, Lu Y, Li H, Hong B, Zheng Y, He J, Yang J, Yi Q. Anti-β2 M monoclonal antibodies kill myeloma cells via cell- and complement-mediated cytotoxicity. Int J Cancer 135(5):1132-41, 9/2014. e-Pub 2/2014. PMID: 24474467.
41. He Z, He J, Liu Z, Xu J, Yi SF, Liu H, Yang J. MAPK11 in breast cancer cells enhances osteoclastogenesis and bone resorption. Biochimie 106:24-32, 11/2014. e-Pub 7/2014. PMCID: PMC4250302.
42. Gu D, Wang S, Kuiatse I, Wang H, He J, Dai Y, Jones RJ, Bjorklund CC, Yang J, Grant S, Orlowski RZ. Inhibition of the MDM2 E3 Ligase induces apoptosis and autophagy in wild-type and mutant p53 models of multiple myeloma, and acts synergistically with ABT-737. PLoS One 9(9):e103015, 2014. e-Pub 9/2014. PMCID: PMC4151993.
43. Lu Y, Zhang M, Wang S, Hong B, Wang Z, Li H, Zheng Y, Yang J, Davis RE, Qian J, Hou J, Yi Q. p38 MAPK-inhibited dendritic cells induce superior antitumour immune responses and overcome regulatory T-cell-mediated immunosuppression. Nat Commun 5:4229, 2014. e-Pub 6/2014. PMCID: PMC4249595.
44. Hong B, Li H, Zhang M, Xu J, Lu Y, Zheng Y, Qian J, Chang JT, Yang J, Yi Q. p38 MAPK inhibits breast cancer metastasis through regulation of stromal expansion. Int J Cancer 136(1):34-43, 1/2015. e-Pub 5/2014. PMCID: PMC4200482.
45. Zhang M, He J, Liu Z, Lu Y, Zheng Y, Li H, Xu J, Liu H, Qian J, Orlowski RZ, Kwak LW, Yi Q, Yang J. Anti-β2-microglobulin monoclonal antibodies overcome bortezomib resistance in multiple myeloma by inhibiting autophagy. Oncotarget 6(11):8567-78, 4/2015. e-Pub 3/2015. PMID: 25895124.

Invited Articles

1. Yang J and Yi Q. Therapeutic monoclonal antibodies for multiple myeloma: an update and future perspectives. Am J Blood Res 1(1):22-33, 6/2011. PMCID: PMC3207269.
2. Liu H, He J, Yang J. Tumor cell p38 MAPK: A trigger of cancer bone osteolysis. Cancer Cell Microenviron 2(1), 1/2015. PMCID: PMC4448135.

Abstracts

1. Qian J, Hong S, Qin H, Wang J, Wei J, Zhang L, Li H, Zheng Y, Lan Y, Yang J, Lu Y, Kwak L, and Yi Q. Active Vaccination with DKK1 Induces Protective and Therapeutic Antitumor Immunity In Multiple Myeloma. Blood (ASH Annual Meeting Abstracts) 116(21) (#3040), 11/2010.
2. Zheng Y, Yang J, Zhang L, Qian J, Matthews J, Wang M, Kwak L, and Yi Q. Novel PI3K Inhibitor Compound A Induces Myeloma Cell Apoptosis and Shows Synergistic Cytotoxicity with Dexamethasone In Multiple Myeloma. Blood (ASH Annual Meeting Abstracts) 116(21) (#4080), 11/2010.
3. Zhang L, Yang J, Qian J, Neelapu S, Kwak L, Wang M, and Yi Q. Role of Microenvironment In Mantle Cell Lymphoma: IL-6 as An Important Survival Factor for Tumor Cells. Blood (ASH Annual Meeting Abstracts) 116(21) (#3929), 11/2010.
4. Qian J, Zheng Y, Wang L, Hong S, Li H, Lu Y, He J, Yang J, Kwak L, and Yi Q. Blockade of B7H1 by Monoclonal Antibodies Enhances Therapeutic Immunity of DKK1 Vaccine in Multiple Myeloma. Blood (ASH Annual Meeting Abstracts) 118(21) (#2941), 11/2011.
5. Wang L, Qian J, Lu Y, Li H, Hong S, Bao H, He D, Liu Z, Zheng Y, He J, Lan Y, Li Y, Neelapu S, Yang J, Wang M, Cai Z, and Yi Q. Expression of B7-H1 in Mantle Cell Lymphoma Leads to Inhibition of T Cell Response to Tumor Cells. Blood (ASH Annual Meeting Abstracts) 118(21) (#2643), 11/2011.
6. Zheng Y, Yang J, Qian J, Hanabuchi S, Liu Z, Lu Y, He J, Li H, Shah J, Lan Y, and Yi Q. P/E Selectins and Their Ligand PSGL-1 Are Crucial for Macrophage-Mediated Multiple Myeloma Chemoresistance. Blood (ASH Annual Meeting Abstracts) 118(21) (#130), 11/2011.
7. Li H, Lu Y, Hong S, Qian J, Liu Z, Zheng Y, Lan Y, He J, Yang J, and Yi Q. Reciprocal Interaction Between Osteoclasts and T Cells: Osteoclasts Inhibit T Cell Proliferation by IDO Produced in Response to T Cell-Derived IFN-{gamma} and CD40 Ligand. Blood (ASH Annual Meeting Abstracts) 118(21) (#694), 11/2011.
8. Liu Z, Zheng Y, Li H, Xu J, He J, Huang E, Lu Y, Park J, Hong B, Zhang M, Qian J, Lin P, Kwak L, Yi Q, and Yang J. Myeloma Cells Exhibit Inhibitory Effect On Osteoclastogenesis. Blood (ASH Annual Meeting Abstracts) 120(21) (#439), 11/2012.
9. He J, Liu Z, Zheng Y, Qian J, Li H, Lu Y, Xu J, Hong B, Zhang M, Lin P, Cai Z, Orlowski R, Kwak L, Yi Q, and Yang J. P38 MAPK Activity in Myeloma Cells Regulates Osteoclast and Osteoblast Activity and Induces Bone Destruction in Vivo. Blood (ASH Annual Meeting Abstracts) 120(21) (#566), 11/2012.
10. Yang J, Xu J, Liu Z, He J, Liu H, Lin P, Orlowski R, Kwak L, and Yi Q. Activation Of Autophagy By Bone Marrow Adipocytes Protects Myeloma Cells From Chemotherapy-Induced Apoptosis. Blood (ASH Annual Meeting Abstracts) 122(21) (#1915), 12/2013.
11. Zhang M, He J, Lu Y, Zheng Y, Hong B, Li H, Liu Z, Xu J, Liu H, Qian J, Yi Q, and Yang J. Microglobulin Monoclonal Antibodies Overcome Bortezomib-Induced Drug Resistance in Multiple Myeloma by Inhibition of Autophagy. Blood (ASH Annual Meeting Abstracts) 122(21) (#929), 12/2013.
12. Yang J, Zhong Y, He J,  Liu Z, Liu H, Lin P, Orlowski R, and Kwak L. Regulation Of DKK-1 Expression By p38 MAPK Signaling Via CREB Myeloma Cells. Blood (ASH Annual Meeting Abstracts) 122(21) (#1917), 12/2013.

Book Chapters

1. Yang J. Tissue Culture Technology and Cell Biological Detection. In: Practical Guide to Molecular Biology Operation. Ed(s) Cao Y. People’s Health Publishing House: China, 2003. PMID: 7117056096.
2. Yang J. Cytokines and Growth Factors. In: Signal Transduction. Ed(s) Huang W and Zhu X. People’s Health Publishing House: China, 2005. PMID: 7117068035.
3. Yang J and Yi Q. Signaling pathways mediating dendritic cells dysfunction in cancer. In: Dendritic Cells in Cancer. Ed(s) Shurin M and Salter R. Springer, 2009. PMID: 978-0-387-88610-7.
4. Lu Y, Yang J and Yi Q. Signaling of Tumor-Induced Immunosuppression of Dendritic Cells. In: The Tumor Immunoenviroment. Ed(s) Shuin MR, Umansky V, Mayguine A. Springer: Netherlands, 2013.